44 Results for "

Pyk2

" in MedChemExpress (MCE) Product Catalog:
Products (44)

44 Results for "Pyk2" in MCE Product Catalog:

32
32 Publications Verification
Art. -Nr.: HY-10459
CAS. Nr.: 717907-75-0
Reinheit:  99.68%
Synonyms: VS-6062
Target:  

FAK Pyk2

Forschungsgebiete:  

Neurological Disease Cancer

PF-562271 (VS-6062) is an orally active, ATP-competitive, reversible FAK/Pyk2 inhibitor, with an IC50 of 1.5 nM for FAK and 13 nM for Pyk2. PF-562271 induces tumor regression, and inhibits tumor growth, invasion and metastasis. PF-562271 exerts no effect on tumor necrosis, angiogenesis or apoptosis in an orthotopic mouse model of pancreatic ductal adenocarcinoma. When combined with Sunitinib (HY-10255A), PF-562271 reduces tumor vascularization, decreases serum alpha-fetoprotein levels and improves cachexia. PF-562271 can be used in research related to prostate cancer, breast cancer, pancreatic cancer, colon cancer, glioblastoma, lung cancer, pancreatic ductal adenocarcinoma and hepatocellular carcinoma [2] .
loading...
    loading...
32
32 Publications Verification
Art. -Nr.: HY-10458
CAS. Nr.: 939791-38-5
Reinheit:  99.17%
Synonyms: VS-6062 (besylate)
Target:  

FAK Pyk2

Forschungsgebiete:  

Neurological Disease Cancer

PF-562271 besylate (VS-6062 besylate) is an orally active, ATP-competitive, reversible FAK/Pyk2 inhibitor, with an IC50 of 1.5 nM for FAK and 13 nM for Pyk2. PF-562271 besylate induces tumor regression, and inhibits tumor growth, invasion and metastasis. PF-562271 besylate exerts no effect on tumor necrosis, angiogenesis or apoptosis in an orthotopic mouse model of pancreatic ductal adenocarcinoma. When combined with Sunitinib (HY-10255A), PF-562271 besylate reduces tumor vascularization, decreases serum alpha-fetoprotein levels and improves cachexia. PF-562271 besylate can be used in research related to prostate cancer, breast cancer, pancreatic cancer, colon cancer, glioblastoma, lung cancer, pancreatic ductal adenocarcinoma and hepatocellular carcinoma [2] .
loading...
    loading...
30
30 Cited Publications
Art. -Nr.: HY-20403
CAS. Nr.: 939791-41-0
Synonyms: VS-6062hydrochloride
Target:  

FAK Pyk2

Forschungsgebiete:  

Neurological Disease Cancer

PF-562271 hydrochloride (VS-6062 hydrochloride) is an orally active, ATP-competitive, reversible FAK/Pyk2 inhibitor, with an IC50 of 1.5 nM for FAK and 13 nM for Pyk2. PF-562271 hydrochloride induces tumor regression, and inhibits tumor growth, invasion and metastasis. PF-562271 hydrochloride exerts no effect on tumor necrosis, angiogenesis or apoptosis in an orthotopic mouse model of pancreatic ductal adenocarcinoma. When combined with Sunitinib (HY-10255A), PF-562271 hydrochloride reduces tumor vascularization, decreases serum alpha-fetoprotein levels and improves cachexia. PF-562271 hydrochloride can be used in research related to prostate cancer, breast cancer, pancreatic cancer, colon cancer, glioblastoma, lung cancer, pancreatic ductal adenocarcinoma and hepatocellular carcinoma [2] .
loading...
    loading...
11
11 Cited Publications
Art. -Nr.: HY-13203
CAS. Nr.: 761437-28-9
Reinheit:  99.77%
Synonyms: TAE226
Forschungsgebiete:  

Endocrinology Cancer

NVP-TAE 226 (TAE226) is a potent and ATP-competitive dual FAK and IGF-1R inhibitor with IC50s of 5.5 nM and 140 nM, respectively. NVP-TAE 226 (TAE226) also effectively inhibits Pyk2 and insulin receptor (InsR) with IC50s of 3.5 nM and 44 nM, respectively [2].
loading...
    loading...
7
7 Cited Publications
Art. -Nr.: HY-10460
CAS. Nr.: 717906-29-1
Reinheit:  99.74%
Target:  

Pyk2 FAK

Forschungsgebiete:  

Cancer

PF-431396 is an orally active dual focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (PYK2) inhibitor, with IC50 values of 2 nM and 11 nM, respectively [2] .
loading...
    loading...
6
6 Cited Publications
Art. -Nr.: HY-18312
CAS. Nr.: 1166393-85-6
Target:  

Pyk2

Forschungsgebiete:  

Metabolic Disease

PF-4618433 is a potent and selective PYK2 inhibitor, with an IC50 of 637 nM. PF-4618433 may be suitable for the research of osteoporosis, craniofacial and appendicular skeletal defects and for targeted bone regeneration [2].
loading...
    loading...
5
5 Cited Publications
Art. -Nr.: HY-134570
CAS. Nr.: 1211825-25-0
Reinheit:  99.75%
Target:  

FAK

ZINC40099027 is a selective FAK activator. ZINC40099027 promotes FAK phosphorylation, without activating its paralogs Pyk2 and Src. ZINC40099027 promotes the wound closure of human intestinal epithelial monolayers and the healing of mouse ulcers by activating FAK. ZINC40099027 can be used for diseases related to gastrointestinal mucosal injury research .
loading...
    loading...
5
5 Cited Publications
Art. -Nr.: HY-15323
CAS. Nr.: 1370261-97-4
Reinheit:  98.07%
Synonyms: P505-15 Hydrochloride
Forschungsgebiete:  

Cancer

PRT062607 (P505-15) Hydrochloride is an orally available Syk inhibitor (IC50: 1 nM) that inhibits inflammation and induction Apoptosis. PRT062607 Hydrochloride exerts potent antitumor activity in tumor xenograft mouse models [2].
loading...
    loading...
5
5 Cited Publications
Art. -Nr.: HY-15324
CAS. Nr.: 1370261-98-5
Reinheit:  99.83%
Synonyms: P505-15 acetate; PRT-2607 acetate; BIIB-057 acetate
Forschungsgebiete:  

Cancer

PRT062607 (P505-15) acetate is an orally available Syk inhibitor (IC50: 1 nM) that inhibits inflammation and induction Apoptosis. PRT062607 acetate exerts potent antitumor activity in tumor xenograft mouse models . [2].
loading...
    loading...
Art. -Nr.: HY-109084
CAS. Nr.: 1384860-29-0
Reinheit:  99.0%
Synonyms: CT-707
Target:  

FAK

Forschungsgebiete:  

Cancer

Conteltinib (CT-707) is a multi-kinase inhibitor targeting FAK, ALK, and Pyk2. Conteltinib exerts significant inhibitory effect on FAK with an IC50 of 1.6 nM .
loading...
    loading...
Art. -Nr.: HY-113788
CAS. Nr.: 1404454-02-9
PF-719 is a highly selective Pyk2 inhibitor with an IC50 value of 17 nM. PF-719 promotes the activation of LKB1 and p38 MAPK. PF-719 blocks synaptic deficits induced by Amyloid-beta oligomers and reverses the inhibition of long-term potentiation induced by β-amyloid oligomers. PF-719 can be used in research related to Alzheimer's disease and autoimmune diseases [2] .
loading...
    loading...
Art. -Nr.: HY-109082
CAS. Nr.: 1703788-21-9
Reinheit:  99.58%
Synonyms: SKI-O-703
Target:  

Syk

Forschungsgebiete:  

Inflammation/Immunology

Cevidoplenib (SKI-O-703) is an orally available inhibitor of spleen tyrosine kinase (Syk), with potential anti-inflammatory and immunomodulating activities. Cevidoplenib is also the mesylate form of SKI-O-592. Cevidoplenib and SKI-O-592 inhibits BCR-mediated survival, proliferation, and differentiation of B cells. And SKI-O-592 potently inhibits multiple kinases with IC50s of 6.2 nM (Syk), 1.859 μM (Jak2), 5.807 μM (Jak3), 0.412 μM (RET), 0.687 μM (KOR), 1.783 μM (FLT3), 16.96 μM (FGFR1), 5.662 μM (FGFR3), and 0.709 μM (Pyk2), respectively [2] .
loading...
    loading...
Art. -Nr.: HY-401485
CAS. Nr.: 1271418-15-5
Target:  

Pyk2 FAK

Forschungsgebiete:  

Cancer

Pyk2-IN-2 (compound 13j) is an inhibitor of Pyk2 with an IC50 of FAK kinase of 0.608 μM .
loading...
    loading...
Art. -Nr.: HY-138825
CAS. Nr.: 1039980-33-0
Reinheit:  ≥95.0%
Target:  

Pyk2

Forschungsgebiete:  

Metabolic Disease

NCGC00188636 is a novel covalent pyruvate kinase (PYK) inhibitor. NCGC00188636 blocks nucleotide binding to the active site of pyruvate kinase. NCGC00188636 can be used for the research of the metabolism of many organisms and cell types.
loading...
    loading...
Art. -Nr.: HY-147219A
Reinheit:  99.84%
SIAIS164018 hydrochloride is a multi-kinase (ALK, EGFR, FAK, PYK2, PTK6) PROTAC degrader, with IC50 values of 2.5 nM and 6.6 nM against ALK and ALK (G1202R), respectively. SIAIS164018 hydrochloride promotes the ubiquitination and degradation of ALK, EGFR, FAK, PYK2 and PTK6. SIAIS164018 hydrochloride induces cell cycle arrest at the G1 phase and triggers cell Apoptosis. SIAIS164018 hydrochloride exhibits preferential inhibitory activity against FER kinase. SIAIS164018 hydrochloride can be used in research related to non-small cell lung cancer, ovarian cancer and triple-negative breast cancer [2] .
loading...
    loading...
Art. -Nr.: HY-W747599
CAS. Nr.: 68652-37-9
Synonyms: ​Tetrasialoganglioside GQ1b sodium
Ganglioside GQ1b (​Tetrasialoganglioside GQ1b) (bovine) sodium is a central and peripheral nervous system ganglioside and an immunostimulator. Ganglioside GQ1b (bovine) sodium modulates NMDA receptor signaling via ERK1/2, PKA, CREB, NR2A, NR2B, and GSK3β, and increases BDNF expression. Ganglioside GQ1b (bovine) sodium reduces Aβ pathology, tau phosphorylation, and APP levels. Ganglioside GQ1b (bovine) sodium can be used for the research of Alzheimer’s disease [2] .
loading...
    loading...
Art. -Nr.: HY-147219
CAS. Nr.: 2353492-68-7
SIAIS164018 is a multi-kinase (ALK, EGFR, FAK, PYK2, PTK6) PROTAC degrader, with IC50 values of 2.5 nM and 6.6 nM against ALK and ALK (G1202R), respectively. SIAIS164018 promotes the ubiquitination and degradation of ALK, EGFR, FAK, PYK2 and PTK6. SIAIS164018 induces cell cycle arrest at the G1 phase and triggers cell Apoptosis. SIAIS164018 exhibits preferential inhibitory activity against FER kinase. SIAIS164018 can be used in research related to non-small cell lung cancer, ovarian cancer and triple-negative breast cancer [2] .
loading...
    loading...
Art. -Nr.: HY-109084A
Synonyms: CT-707 tetrahydrochloride
Target:  

FAK

Forschungsgebiete:  

Cancer

Conteltinib tetrahydrochloride (CT-707 tetrahydrochloride) is the tetrahydrochloride salt form of Conteltinib (HY-109084). Conteltinib tetrahydrochloride is the inhibitor for FAK (IC50=1.6 nM), ALK, and Pyk2. Conteltinib tetrahydrochloride exhibits a synergistic anti-tumor efficacy with Cabozantinib (HY-13016) .
loading...
    loading...
Art. -Nr.: HY-178969
Target:  

FAK Pyk2 Apoptosis

Forschungsgebiete:  

Neurological Disease Cancer

GZD-257 is a brain-penetrant, ATP-competitive FAK inhibitor (IC50 = 14.3 nM), performing 4.77-fold selectivity with FAK to Pyk2 (IC50 = 68.2 nM). GZD-257 can significantly induce apoptosis of U118MG cells and arrest the cell cycle at the G2/M phase. GZD-257 can be used for the study of Glioblastoma (GBM) .
loading...
    loading...
Art. -Nr.: HY-169953
Target:  

Pyk2

Forschungsgebiete:  

Metabolic Disease

BT-Amide is the orally active inhibitor for Pyk2 kinase with IC50 of 44.69 nM. BT-Amide prevents glucocorticoid-induced bone loss, exhibits bone protective activity in C57BL/6 mouse .
loading...
    loading...